Panbela Therapeutics, Inc. (PBLA)
OTCMKTS
· Delayed Price · Currency is USD
0.380
+0.060 (18.75%)
Oct 30, 2024, 3:38 PM EDT
Panbela Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 0.06 | 2.58 | 1.29 | 11.87 | 9.02 | 2.45 | Upgrade
|
Cash & Short-Term Investments | 0.06 | 2.58 | 1.29 | 11.87 | 9.02 | 2.45 | Upgrade
|
Cash Growth | -99.18% | 100.62% | -89.17% | 31.53% | 268.40% | 74.31% | Upgrade
|
Other Receivables | 0.32 | 0.18 | 0.05 | 0.32 | 0.32 | 0.36 | Upgrade
|
Receivables | 0.32 | 0.18 | 0.05 | 0.32 | 0.32 | 0.36 | Upgrade
|
Prepaid Expenses | 0.39 | 0.3 | 0.44 | 0.09 | 0.41 | 0.28 | Upgrade
|
Total Current Assets | 0.77 | 3.06 | 1.78 | 12.28 | 9.76 | 3.09 | Upgrade
|
Other Long-Term Assets | 8.64 | 8.74 | 3.2 | 0.59 | 0.06 | 0.05 | Upgrade
|
Total Assets | 9.41 | 11.8 | 4.98 | 12.87 | 9.81 | 3.14 | Upgrade
|
Accounts Payable | 14.29 | 9.94 | 2.87 | 0.64 | 0.55 | 0.6 | Upgrade
|
Accrued Expenses | 1.5 | 1.38 | 3.32 | 2.02 | 0.81 | 0.3 | Upgrade
|
Short-Term Debt | - | - | 0.65 | - | - | 0.74 | Upgrade
|
Current Portion of Long-Term Debt | 1 | 1 | 1 | - | - | 0.12 | Upgrade
|
Total Current Liabilities | 16.79 | 12.32 | 7.83 | 2.66 | 1.37 | 1.76 | Upgrade
|
Long-Term Debt | 3.19 | 4.19 | 5.19 | - | - | - | Upgrade
|
Total Liabilities | 19.98 | 16.51 | 13.03 | 2.66 | 1.37 | 1.76 | Upgrade
|
Common Stock | 0.01 | - | - | - | 0.01 | 0.01 | Upgrade
|
Additional Paid-In Capital | 128.22 | 120.04 | 82.29 | 66.24 | 54.85 | 42.33 | Upgrade
|
Retained Earnings | -139.76 | -125.5 | -91.09 | -56.16 | -46.03 | -41.26 | Upgrade
|
Treasury Stock | -0 | -0 | - | - | - | - | Upgrade
|
Comprehensive Income & Other | 0.96 | 0.75 | 0.76 | 0.13 | -0.38 | 0.31 | Upgrade
|
Shareholders' Equity | -10.57 | -4.71 | -8.05 | 10.21 | 8.45 | 1.39 | Upgrade
|
Total Liabilities & Equity | 9.41 | 11.8 | 4.98 | 12.87 | 9.81 | 3.14 | Upgrade
|
Total Debt | 4.19 | 5.19 | 6.84 | - | - | 0.86 | Upgrade
|
Net Cash (Debt) | -4.14 | -2.62 | -5.56 | 11.87 | 9.02 | 1.59 | Upgrade
|
Net Cash Growth | - | - | - | 31.53% | 467.06% | 50.81% | Upgrade
|
Net Cash Per Share | -1.98 | -24.07 | - | - | - | - | Upgrade
|
Filing Date Shares Outstanding | 4.85 | 4.85 | 0.02 | - | - | - | Upgrade
|
Total Common Shares Outstanding | 4.85 | 0.48 | - | - | - | - | Upgrade
|
Working Capital | -16.02 | -9.26 | -6.06 | 9.62 | 8.39 | 1.33 | Upgrade
|
Book Value Per Share | -2.18 | -9.81 | - | - | - | - | Upgrade
|
Tangible Book Value | -10.57 | -4.71 | -8.05 | 10.21 | 8.45 | 1.39 | Upgrade
|
Tangible Book Value Per Share | -2.18 | -9.81 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.